$0.61
1.67%
Nasdaq, Mon, Aug 04 2025
ISIN
CA58490H1073
Symbol
MDNA

Medicenna Therapeutics Corp Stock price

$0.61
-0.04 5.69% 1M
-0.28 31.69% 6M
-0.54 46.72% YTD
-0.94 60.65% 1Y
-0.96 61.15% 3Y
-3.32 84.49% 5Y
-0.89 59.22% 10Y
-0.89 59.22% 20Y
Nasdaq, Closing price Mon, Aug 04 2025
+0.01 1.67%
ISIN
CA58490H1073
Symbol
MDNA
Industry

Key metrics

Basic
Market capitalization
$41.9m
Enterprise Value
$24.0m
Net debt
positive
Cash
$18.0m
Shares outstanding
78.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 129.2
EV/Sales
- | 74.0
EV/FCF
negative
P/B
3.0
Financial Health
Equity Ratio
67.3%
Return on Equity
-61.8%
ROCE
-85.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $324.2k
EBITDA
$-14.8m | -
EBIT
$-14.8m | $-16.9m
Net Income
$-8.6m | $-16.0m
Free Cash Flow
$-12.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-9.0% | -
EBIT
-9.3% | -14.1%
Net Income
53.6% | -86.9%
Free Cash Flow
-1.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -4,940.9%
Free Cash Flow
-
More
EPS
$-0.1
FCF per Share
$-0.2
Short interest
0.7%
Employees
16
Rev per Employee
$0.0
Show more

Is Medicenna Therapeutics Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,032 stocks worldwide.

Medicenna Therapeutics Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Medicenna Therapeutics Corp forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Medicenna Therapeutics Corp forecast:

Buy
88%
Hold
13%

Financial data from Medicenna Therapeutics Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.29 4.29
25% 25%
-
- Research and Development Expense 10 10
34% 34%
-
-15 -15
9% 9%
-
- Depreciation and Amortization 0.04 0.04
-
-
EBIT (Operating Income) EBIT -15 -15
9% 9%
-
Net Profit -8.57 -8.57
54% 54%
-

In millions USD.

Don't miss a Thing! We will send you all news about Medicenna Therapeutics Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company which engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company was founded by Fahar Merchant and Rosemina Merchant on February 2, 2015 and is headquartered in Toronto, Canada.

Head office Canada
CEO Fahar Merchant
Employees 16
Founded 2015
Website www.medicenna.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today